Psychological Effect of Explicit Recall After Sedation (PEERS) (PEERS)

Psychological Effect of Explicit Recall After Sedation

Awareness, or explicit recall, under sedation is often intended and expected by anesthesiologists and is assumed that does not associate with any sequelae. Thus, awareness under sedation is a common event and is estimated to occur in around one-quarter of patients in our population. However, two recent studies suggested some patients with awareness under sedation have comparable psychological sequelae to those patients with awareness during general anesthesia. As such, we plan to conduct a a single center, prospective cohort study to determine the incidence of explicit recall under sedation/regional anaesthesia in adults, and to identify whether explicit recall experiences - or specific elements of those experiences (e.g. feeling pain and paralysis) - were associated with psychiatric sequelae.

In this study, we will prospectively include 2500 patients who will be scheduled to have total hip and knee joint replacement surgery under regional anesthesia and sedation at University Hospital, London Health Sciences Center.

All participants will be assessed at four separate time points including:

  1. Enrollment/Surgical Preparatory Area (~ 2 hours before surgery)
  2. Post Anesthesia Care Unit (assessment will be conducted in PACU prior to discharge, within a maximum window of 6 hours from PACU admission)
  3. Postoperative day one (in hospital)
  4. Postoperative 6 weeks (expected to be after discharge via telephone or in-person in clinic)

Study Overview

Detailed Description

Demographic and perioperative variables will be summarized. Descriptive statistics will be used to examine the incidence of awareness under sedation. We will further report the incidence of awareness with or without psychological sequalae, as well as the immediate and delayed awareness. We will also summarize the recall experience, initial emotional responses toward the event of awareness, as well as the patient satisfaction.

The psychological consequences will be defined and graded using the PHQ-9 (patient health questionnaire-9) and PCL-S (PTSD Checklist Stressor - S) questionnaires. The severity of harm using modified National Patient Safety Agency (NPSA) will also be described.

For the primary analysis, to assess the risk of explicit recall experience towards the development of PTSD and depression, we performed univariable logistic regression to assess whether explicit recall will be associated with either co-primary outcome. This will be followed by an assessment of individual element of recall experiences, such as auditory recall, feeling pressure, feeling pain and paralysis, etc. Multivariable logistic regression analysis will also performed to adjust for potential confounders

For the secondary analysis, we will further perform logistic regression analysis to assess the potential risk factors for explicit recall. The potential risk factors to fit into the models include: i) patient factors: obesity, obstructive sleep apnoea or any cardiopulmonary diseases that lead to sedation failure, history of psychiatric disease, ii) anestheteic factors such as the choice of sedatives, iii) patient expectation (assessed by NAP5 method), iv) duration and experiences of explicit recall (e.g. auditory, tactile or pain).

Additionally, we will assess patient expectations and communication between the patients and healthcare providers.

To assess the impact of surgery on the development of psychiatric symptoms, we will evaluate changes in the severity of depressive symptoms before and after surgery. We will also estimate the mental healthcare burden by determining the number of new psychiatric consultations potentially required.

P values <0.05 were accepted as statistically significant.

Study Type

Observational

Enrollment (Actual)

2500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • London, Ontario, Canada, N6A 5A5
        • London Health Science Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients scheduled to undergo orthopedic or joint replacement surgeries under sedation/regional anesthesia at University Hospital located in London, Ontario, Canada.

Description

Inclusion Criteria:

  1. Adult patient (> or = 18 years old)
  2. Scheduled to have orthopedic surgery or joint replacement therapy under sedation/regional anesthesia
  3. Patient is able to communicate in English
  4. ASA I-IV

Exclusion Criteria:

  1. Unable to obtain informed consent
  2. Patient received General Anesthesia (GA) or conversion to GA during their surgical procedures
  3. Unable to conduct the survey such as language barrier, overt psychiatric disorder thought to interfere with the reliability of the interview (e.g. dementia etc)
  4. Patient who is expected to require mechanical ventilation at postoperative period (i.e. unable to perform surveys at Post-Anesthesia Care Unit (PACU) and postoperative day one)
  5. Unable to follow up via phone or attend a postoperative follow-up visit at postoperative 6 weeks

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Explicit recall
Time Frame: Assessment will be conducted in PACU prior to discharge, within a maximum window of 6 hours from PACU admission
Explicit recall will be assessed by Modified Brice Questionnaire
Assessment will be conducted in PACU prior to discharge, within a maximum window of 6 hours from PACU admission

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Explicit Recall
Time Frame: Postoperative Day 1

Explicit recall will be assessed by Modified Brice Questionnaire

The Michigan Awareness Classification is used to report the levels of sensation during awareness. 5 Levels of sensation are classified as auditory, tactile, pain, paralysis, or pain and paralysis. A designation of 'D' for distress is used for patient reports of fear, anxiety, suffocation, sense of doom, sense of impending death, or similar reports that indicated emotional distress during the explicit recall experience.

Postoperative Day 1
Sensation During Awareness
Time Frame: Postoperative Day 1

The Michigan Awareness Classification - Michigan Score

The Michigan Awareness Classification is used to report the levels of sensation during awareness. 5 Levels of sensation are classified as auditory, tactile, pain, paralysis, or pain and paralysis. A designation of 'D' for distress is used for patient reports of fear, anxiety, suffocation, sense of doom, sense of impending death, or similar reports that indicated emotional distress during the explicit recall experience.

Postoperative Day 1
Details of recall experience
Time Frame: Postoperative Day 1

Light, smell, and other feelings

The Michigan Awareness Classification is used to report the levels of sensation during awareness. 5 Levels of sensation are classified as auditory, tactile, pain, paralysis, or pain and paralysis. A designation of 'D' for distress is used for patient reports of fear, anxiety, suffocation, sense of doom, sense of impending death, or similar reports that indicated emotional distress during the explicit recall experience.

Postoperative Day 1
Post Traumatic Stress Disorder
Time Frame: Postoperative 6 weeks
PCL-C Questionnaire
Postoperative 6 weeks
Depression
Time Frame: Postoperative 6 weeks
PHQ-9 Questionnaire
Postoperative 6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jason Chui, MD, University of Western Ontario, Canada

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 16, 2021

Primary Completion (Actual)

March 26, 2024

Study Completion (Actual)

March 26, 2024

Study Registration Dates

First Submitted

October 27, 2020

First Submitted That Met QC Criteria

February 9, 2021

First Posted (Actual)

February 10, 2021

Study Record Updates

Last Update Posted (Actual)

April 18, 2025

Last Update Submitted That Met QC Criteria

April 15, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Subscribe